Literature DB >> 12649400

The association of antinuclear antibodies with organ involvement and survival in systemic sclerosis.

R Hesselstrand1, A Scheja, G Q Shen, A Wiik, A Akesson.   

Abstract

OBJECTIVES: To study the frequency and specificity of antinuclear antibodies (ANA) and their association with internal organ involvement and survival in systemic sclerosis (SSc).
METHODS: Sera from 276 SSc patients were analysed by an indirect immunofluorescence (IIF) technique with HEp-2 cells as a substrate to categorize centromeric (ACA), nucleolar, speckled and homogeneous nuclear IIF patterns. Specific ANA were determined as follows: anti-DNA topoisomerase I (anti-topo I) by double immunodiffusion, anti-U1 RNP by passive haemagglutination, anti-RNA polymerase I, II and III (anti-RNAP) and anti-histone (AHA) antibodies by enzyme immunoassays. During the follow-up of 7.0+/-4.5 (mean+/-S.D.) yr the occurrence of clinical manifestations and internal organ involvement was registered.
RESULTS: ANA were present in 84% of the patients. The most common patterns of the IIF were speckled (41%), homogeneous (25%), nucleolar (24%) and centromeric (18%). A nucleolar pattern was associated with pulmonary fibrosis (P < 0.01) and cardiomegaly (P < 0.05). ACA were related to organic vasculopathy (P < 0.05) and renal involvement (P < 0.01), but not to pulmonary fibrosis (P < 0.01). Anti-topo I were present in 9.4%, anti-U1 RNP in 21%, anti-RNAP in 22% and AHA in 16% of the patients. Pulmonary involvement was more common in patients with anti-topo I (P < 0.05), whereas AHA-positive patients were characterized by cardiac (P < 0.05), pulmonary (P < 0.05) and renal (P < 0.05) involvement. A nucleolar IIF pattern and AHA were both associated with a decreased survival [relative risk of death 1.71 (P < 0.05) and 2.36 (P < 0.01), respectively].
CONCLUSIONS: AHA and a nucleolar HEp-2 cell pattern may indicate critical organ involvement and predict a reduced survival in SSc patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12649400     DOI: 10.1093/rheumatology/keg170

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  38 in total

1.  Vascular leak is a central feature in the pathogenesis of systemic sclerosis.

Authors:  Tracy M Frech; Monica P Revelo; Stavros G Drakos; Maureen A Murtaugh; Boaz A Markewitz; Allen D Sawitzke; Dean Y Li
Journal:  J Rheumatol       Date:  2012-06-01       Impact factor: 4.666

Review 2.  Immunomodulatory therapy for SSc: will high-intensity immunosuppression with stem cell rescue improve outcome?

Authors:  Leslie J Crofford
Journal:  Curr Rheumatol Rep       Date:  2005-04       Impact factor: 4.592

Review 3.  Biomarkers in the management of scleroderma: an update.

Authors:  Giuseppina Abignano; Maya Buch; Paul Emery; Francesco Del Galdo
Journal:  Curr Rheumatol Rep       Date:  2011-02       Impact factor: 4.592

4.  Gastric slow waves, gastrointestinal symptoms and peptides in systemic sclerosis patients.

Authors:  T A McNearney; H S Sallam; S E Hunnicutt; D Doshi; D E Wollaston; M D Mayes; J D Z Chen
Journal:  Neurogastroenterol Motil       Date:  2009-06-30       Impact factor: 3.598

5.  Anti-centromere antibody is an independent risk factor for chronic kidney disease in patients with primary biliary cirrhosis.

Authors:  Shintaro Mandai; Eiichiro Kanda; Yohei Arai; Suguru Hirasawa; Toshiyuki Hirai; Shota Aki; Naoto Inaba; Makoto Aoyagi; Hiroyuki Tanaka; Takaaki Ikeda; Teiichi Tamura; Sei Sasaki
Journal:  Clin Exp Nephrol       Date:  2012-12-26       Impact factor: 2.801

6.  Left atrial volume and N-terminal pro-B type natriuretic peptide are associated with elevated pulmonary artery pressure in patients with systemic sclerosis.

Authors:  Theodoros Dimitroulas; Georgios Giannakoulas; Klio Papadopoulou; Tilemahos Sfetsios; Haralambos Karvounis; Hariklia Dimitroula; Despina Parcharidou; Georgios Koliakos; Alexandros Garyfallos; Ioannis Styliadis; Loukas Settas
Journal:  Clin Rheumatol       Date:  2010-06-05       Impact factor: 2.980

Review 7.  [Systemic sclerosis - diagnosis and classification].

Authors:  E Genth; T Krieg
Journal:  Z Rheumatol       Date:  2006-07       Impact factor: 1.372

8.  Plasma endogenous enkephalin levels in early systemic sclerosis: clinical and laboratory associations.

Authors:  Terry A McNearney; K A Sluka; C Ahn; J D Reveille; Michael Fischbach; Maureen D Mayes
Journal:  Clin Exp Rheumatol       Date:  2010-06-10       Impact factor: 4.473

Review 9.  Autoantibodies in systemic sclerosis (scleroderma): clues for clinical evaluation, prognosis and pathogenesis.

Authors:  Alfred Grassegger; Gabriela Pohla-Gubo; Margret Frauscher; Helmut Hintner
Journal:  Wien Med Wochenschr       Date:  2008

10.  Systemic sclerosis: demographic, clinical and serological features in 100 Iranian patients.

Authors:  Hadi Poormoghim; Alireza Salek Moghadam; Maziar Moradi-Lakeh; Mehrzad Jafarzadeh; Behnam Asadifar; Mohsen Ghelman; Elham Andalib
Journal:  Rheumatol Int       Date:  2013-01-24       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.